SCHEMBL5761847

SCHEMBL5761847

C=CCC(NC(=O)c1ccc(OC)cc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.57
TAS1R3 Q7RTX0 2/20 0.56
TAS1R1 Q7RTX1 2/20 0.56
CA2 P00918 3/20 0.55
ALDH1A1 P00352 5/20 0.50
CA1 P00915 2/20 0.50
CYP3A4 P08684 1/20 0.50
LMNA P02545 2/20 0.49
PTPN1 P18031 1/20 0.48
PLK1 P53350 1/20 0.47
FOLH1 Q04609 1/20 0.47
CTSL P07711 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759561 0.89 PKM (0.57) PKMTAS1R3TAS1R1CA2ALDH1A1
SCHEMBL5760015 0.85 PKM (0.53) PKMTAS1R3TAS1R1CA2ALDH1A1
SCHEMBL9829566 0.82 CA2 (0.63) TAS1R3TAS1R1CA2ALDH1A1CA1
SCHEMBL9829563 0.82 CA2 (0.63) TAS1R3TAS1R1CA2ALDH1A1CA1
SCHEMBL712558 0.82 FOLH1 (0.50) CA2ALDH1A1CA1LMNAPTPN1
SCHEMBL12877478 0.82 FOLH1 (0.50) CA2ALDH1A1CA1LMNAPTPN1
SCHEMBL9830112 0.81 CA2 (0.58) TAS1R3TAS1R1CA2ALDH1A1CA1
SCHEMBL28524085 0.81 CA2 (0.59) TAS1R3TAS1R1CA2ALDH1A1CA1
SCHEMBL18979327 0.81 CA2 (0.59) TAS1R3TAS1R1CA2ALDH1A1CA1
SCHEMBL9830098 0.81 CA2 (0.58) TAS1R3TAS1R1CA2ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392295-B1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2006-05-31 EP disclosed
EP-1392295-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2004-03-03 EP disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
WO-2002092084-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG PKM 946/4885TAS1R3 1796/4885TAS1R1 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.